Roche’s Hansoh ADC Deal Is Worth Over $15.5 Billion, With $400 Million Upfront for Programmes Still in the Lab
Roche is paying platform money for ADCs that do not exist yet, five times what it paid Hansoh for a clinical asset in 2025.
Drug conjugates
Merck and Daiichi Pulled an ADC Filing as GSK Paid $110 Million for a KRAS Payload
Crowded topoisomerase I ADCs face a higher bar, while money moves to RAS payloads, bispecific ADCs and discovery tools.
Merck’s $4 Billion Daiichi ADC Pact Takes Its Third FDA Setback in Three Years
The $4bn deal’s first return keeps slipping toward 2028, the year Keytruda begins to lose protection.
The Year’s Two Largest Conjugate Deals Were Not ADCs, and Not Cancer Drugs
Buyers stopped paying for conjugate drugs and started paying for conjugate chemistry. The year’s two biggest cheques bought neither an ADC nor a cancer drug.
Pathos Put 6% Down on a Phase III ADC, and Alphamab Kept the Market It Can Actually Reach
Fresenius describes an end to end biopharma business. Dr. Reddy’s developed, made and filed this rituximab. Fresenius is only the channel.